Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

[1]  M. Schwaiger,et al.  Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[2]  R. Hicks,et al.  Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution , 2019, Cancer Imaging.

[3]  T. Çermik,et al.  Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands , 2019, The Journal of Nuclear Medicine.

[4]  B. Tran,et al.  Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. , 2019, Journal of Clinical Oncology.

[5]  R. Epstein,et al.  Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA‐617 Therapy for Metastatic Castration‐Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression , 2019, Clinical genitourinary cancer.

[6]  Barbara E Hertz,et al.  A tribute to Dr. Saul Hertz: The discovery of the medical uses of radioiodine , 2019, World journal of nuclear medicine.

[7]  D. Murphy,et al.  Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. , 2019, European urology oncology.

[8]  W. Wadsak,et al.  Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  G. Feldmann,et al.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  W. Brenner,et al.  Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies , 2018, The Journal of Nuclear Medicine.

[11]  W. Weber,et al.  Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[12]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[13]  O. Caffo,et al.  Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? , 2018, Front. Cell Dev. Biol..

[14]  F. Bénard,et al.  Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model , 2018, The Journal of Nuclear Medicine.

[15]  K. Rahbar,et al.  [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. , 2018, The Lancet. Oncology.

[16]  D. O’Keefe,et al.  A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies , 2018, The Journal of Nuclear Medicine.

[17]  D. Bailey,et al.  A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol , 2018, BJU international.

[18]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[19]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? , 2018, The Journal of Nuclear Medicine.

[20]  Michael S Hofman,et al.  Accuracy of Dose Calibrators for 68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment , 2018, The Journal of Nuclear Medicine.

[21]  M. Rubin,et al.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study , 2018, European urology.

[22]  R. Baum,et al.  Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept , 2018, Nuclear Medicine and Molecular Imaging.

[23]  F. Giesel,et al.  Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study , 2017, The Journal of Nuclear Medicine.

[24]  R. Fimmers,et al.  Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy , 2017, Oncotarget.

[25]  K. Rahbar,et al.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Rolf Fimmers,et al.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Frederick D. Grant,et al.  Saul Hertz, MD, and the birth of radionuclide therapy , 2017, EJNMMI Physics.

[28]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[29]  G. Feldmann,et al.  The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  R. Fimmers,et al.  Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617 , 2017, The Journal of Nuclear Medicine.

[31]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[32]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[33]  G. Böning,et al.  Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer , 2016, Oncotarget.

[34]  M Essler,et al.  PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  A. Seth,et al.  177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Clemens Decristoforo,et al.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Cheung.  Stereotactic body radiotherapy for oligoprogressive cancer. , 2016, The British journal of radiology.

[39]  M. Schwaiger,et al.  Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. , 2016, The Journal of urology.

[40]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[41]  M. Katsogiannou,et al.  The hallmarks of castration-resistant prostate cancers. , 2015, Cancer treatment reviews.

[42]  U. Haberkorn,et al.  PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[43]  Nitya V. Sharma,et al.  The biology of castration-resistant prostate cancer. , 2015, Current problems in cancer.

[44]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  M. Loda,et al.  Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[46]  Stanley J. Goldsmith,et al.  Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[47]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  David J. Kerr,et al.  Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.